The recent fine imposed on HSBC Life for "setting unreasonable medical insurance deductible clauses" and having a "health insurance division not meeting regulatory operational conditions" has drawn significant attention, not for the amount but for the unusual nature of the violations.
The company responded that the fine resulted from issues found during a routine regulatory on-site inspection and that it "has completed rectifications." However, the penalty may hint at deeper issues. An analysis of its financial reports from 2021 to 2025 reveals that the company's complaint volume has generally trended upward over the past five years, increasing more than threefold. The 2025 report, which for the first time disclosed complaints by product type, shows that health insurance accounted for over 30% of complaints, despite contributing less than 1% of the company's revenue.
The penalty undoubtedly reflects issues in the company's internal control management. Furthermore, since completing its transition from a joint venture to a wholly foreign-owned enterprise in 2021, HSBC Life has undertaken four capital increases in five years, raising market questions about whether it is "aggressively expanding its capital base while persistent management challenges remain."
Uncommon Violations and a Surge in Complaints
Recently, the Shanghai Financial Regulatory Bureau issued an administrative penalty targeting HSBC Life and relevant responsible individuals. The notice listed three main violations: "imprudent valuation of equity investments," "setting unreasonable medical insurance deductible clauses," and "health insurance division not meeting regulatory operational conditions."
For these violations, the regulator issued a warning and imposed a fine of 170,000 yuan on HSBC Life. Former investment operations manager Hong Yiwan also received a warning and a 40,000 yuan fine for the "imprudent valuation of equity investments."
The disclosure of the penalty drew market attention, particularly due to the rarity of the latter two violations. Regarding the setting of medical insurance payout clauses, regulatory constraints have been continuously strengthened in recent years, with relevant guidelines updated almost annually. In May of this year, the National Financial Regulatory Administration released the "Negative List for Life Insurance Products (2026 Edition)," marking the seventh update since its initial release in 2018.
The latest version of the negative list added prohibitions and red lines for medical insurance products, including banning "medical insurance products with excessively high deductibles or excessively low payout ratios" and "fixed-benefit medical subsidy products with excessively low coverage amounts." These directly target the common design issues of "low coverage, high marketing hype" in the market's medical insurance products.
The penalty may also have a backstory. An analysis of HSBC Life's financial reports from the past five years shows complaint volumes of 68 cases in 2021, 79 in 2022, 119 in 2023, 280 (including 40 duplicate complaints, meaning 240 after deduplication) in 2024, and 238 (deduplicated) in 2025, representing a 2.5-fold increase over the five-year period.
By business category in 2025, the highest proportion of complaints related to sales issues, totaling 106 cases or 45% of the total. This was followed by 59 cases (25%) related to policy servicing and surrender issues, 32 cases (13%) related to other policy servicing problems, and 3 cases (1%) related to claims and value-added services. In 2024, 26 complaints (9%) were related to underwriting, renewal, claims, and value-added services. In earlier years, complaints also arose from issues like "customer misunderstanding," which accounted for 16% of complaints in 2023.
The violation "health insurance division not meeting regulatory operational conditions" is even more unusual, and health insurance occupies an "awkward" position within HSBC Life's product portfolio. According to the 2025 annual report, the company's annual insurance business revenue was 13.605 billion yuan, a 3.9% increase from 2024. Life insurance contributed the absolute majority, with revenue of 13.474 billion yuan, accounting for over 99%, while health insurance revenue was only 130 million yuan, a mere 0.96%.
Despite contributing less than 1% of business revenue, health insurance accounted for over one-third of all complaints. In 2025, HSBC Life disclosed complaints by product type for the first time, showing 82 cases related to health insurance, constituting 34.5% of the total. This was only 32 cases fewer than the 114 complaints for life insurance, which contributed over 99% of business revenue. Compared longitudinally, the number of health insurance complaints in 2025 already exceeded the total for the entire year of 2022.
Rapid Expansion Drains Solvency, Prompting Four Capital Infusions
Regarding this penalty, HSBC Life stated it was the outcome of issues identified during a routine regulatory on-site inspection of the company. The company said it attached great importance to the problems pointed out by the regulator, took swift action to complete rectifications, and its operations are currently normal.
"Going forward, we will continue to strictly implement regulatory requirements, resolutely comply with compliance management standards, continuously improve the level and effectiveness of internal controls, and ensure all business activities are conducted in accordance with laws and regulations," HSBC Life added.
Prior to receiving this fine, HSBC Life frequently appeared in news reports in connection with its capital increase activities. Established in June 2009, HSBC Life belongs to the HSBC Holdings PLC group, one of the world's largest banking and financial services institutions with a 160-year history. Initially, HSBC Life entered the Chinese insurance market as a 50-50 joint venture between the HSBC group and National Trust. Following the relaxation of regulatory restrictions on foreign shareholders' stakes in life insurers in China, HSBC Life completed its strategic transition from a joint venture to a wholly foreign-owned enterprise in 2021, with HSBC Insurance (Asia) becoming its sole shareholder.
In the nearly five years since, HSBC Life has received four capital injections from its shareholder, HSBC Insurance, with its registered capital rising from 1.025 billion yuan to 3.232 billion yuan. The latest capital increase of 556 million yuan occurred just last month.
This frequency is not low, and the intensive capital increases correspond to the pressure on solvency from business expansion. Based on an analysis of HSBC Life's financial reports, the company's premium scale has grown rapidly in recent years: 1.874 billion yuan in 2020, 2.446 billion in 2021. Growth accelerated further after the transition to wholly foreign-owned status, reaching 3.725 billion in 2022, 7.311 billion in 2023, 13.089 billion in 2024, and 13.605 billion in 2025, representing a cumulative increase of over 600% in five years.
In terms of solvency, according to HSBC Life's solvency report, as of the end of the first quarter of this year, its core solvency adequacy ratio was 130.39%, and its comprehensive solvency adequacy ratio was 184.61%, down approximately 21 and 23 percentage points, respectively, from the end of the previous quarter.
"Business expansion indeed brings natural capital consumption, which is a practical consideration for capital increases," HSBC Life Chairman Cheng Siyun recently stated in a media interview. She noted that the four consecutive capital increases were not simply about "transferring money into the account," nor were they solely for bolstering the safety margin of solvency. They were also aimed at accumulating a thicker capital foundation for deepening its presence in the Chinese market.
In fact, the path to becoming a wholly foreign-owned enterprise was chosen against this backdrop. Unlike AIA's "branch-to-subsidiary" conversion model, HSBC Life's "joint venture to wholly foreign-owned" transition represents another model for foreign insurers' strategic layouts in China. When the transition was completed in 2021, HSBC Life executives stated that having a wholly-owned life insurance subsidiary would help the company more flexibly achieve its business growth plans. At the time, analysis suggested that the "branch-to-subsidiary" model primarily seeks to maximize operational autonomy, while the "joint venture to wholly foreign-owned" model emphasizes the advantages of global resource integration.
"China has become the world's second-largest life insurance market and continues to grow. However, indicators like insurance penetration and density still have room for improvement compared to developed countries and regions—this signifies long-term incremental opportunities," Cheng Siyun further commented.
Betting on the Bancassurance Channel and Building Resilience
What channel has HSBC Life relied on to grow its premium scale? The answer is leveraging the extensive branch network of its parent bank to focus on the bancassurance channel, while also targeting high-net-worth clients with its foreign brand. Looking at insurance business revenue by channel, HSBC Life's first-quarter solvency report shows it achieved written premiums of 4.801 billion yuan for the quarter, of which the bancassurance channel contributed 4.019 billion yuan, accounting for over 80%.
However, while betting on the bancassurance channel has driven premium growth, the rising costs in fees and commissions cannot be ignored. Financial reports show that the company's fees and commission expenses from 2020 to 2025 were 83.21 million yuan, 166 million, 210 million, 406 million, 640 million, and 622 million yuan, respectively, showing rapid growth that has, to some extent, compressed the company's profit margin.
"HSBC Life can achieve lower customer acquisition costs and higher efficiency in scale expansion through the bancassurance channel, but a single-channel structure makes performance dependent on the bank's sales rhythm. Coupled with intense competition in the bancassurance sector, this creates operational uncertainty. Furthermore, the bancassurance channel has long focused on savings-type products, which can easily lead to high liability-side costs," an industry insider pointed out.
Additionally, affected by the consecutive annual increases in insurance liability reserves and fluctuations in fair value gains/losses, HSBC Life did not achieve profitability for several years after its transition. Financial reports show net profits of 6.56 million yuan in 2020, followed by losses of -225 million in 2021, -541 million in 2022, and -85 million in 2023. It only returned to profitability in 2024, with a net profit of 195 million yuan. In 2025, it achieved a net profit of 180 million yuan, a year-on-year decrease of 7.69%.
The return to profitability in 2024 was also related to high investment returns that year, with a comprehensive investment return rate of 7.92%. However, the investment return rate for 2025 was 3.82%, and the comprehensive investment return rate dropped significantly to 0.99%.
Facing the current low-interest-rate environment, where the industry is shifting from "scale-driven" to a refined "value-driven" approach, how will HSBC Life adapt to the new external conditions? How will it enhance its risk resilience while strengthening internal management? Regarding the latest capital increase, Chairman Cheng Siyun stated that the funds will focus on four areas: business development, financial returns, risk control, and core capability building.
In terms of business development, funds will be allocated for product upgrades and innovation, actively exploring opportunities in areas like commercial pensions and innovative health insurance. The company will also deepen cooperation in the bancassurance and agency channels, leveraging the advantages of an "integrated business cooperation model." Regarding core capability building, she emphasized areas including asset-liability management, investment capabilities, and operational service capabilities, describing these as the "internal strength" for the company's sustainable development.
On compliance issues, Cheng Siyun also noted that HSBC's corporate DNA dictates its attitude towards risk—always placing safety and compliance as the cornerstone of development. She outlined several characteristics of the company's management framework: first, a three-lines-of-defense, company-wide risk control system that embeds risk management into every business process; second, a proactive compliance culture with ongoing standardized compliance training; and third, an international perspective on asset-liability management, drawing on the group's experience managing in low-interest-rate environments across multiple global markets and applying those lessons to asset-liability matching in the Chinese market.
Comments